EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mitochondrial inhibitors: a new horizon in breast cancer therapy

Yalan Yan, Sijie Li, Lanqian Su, Xinrui Tang, Xiaoyan Chen, Xiang Gu, Guanhu Yang, Hao Chi, Shangke Huang

Frontiers in Pharmacology · 04.07.2024 · 15

DOI: 10.3389/fphar.2024.1421905 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.07.2024. Verfasst von Yalan Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College, Southwest Medical University, Luzhou, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer, due to resistance to standard therapies such as endocrine therapy, anti-HER2 therapy and chemotherapy, continues to pose a major health challenge. A growing body of research emphasizes the heterogeneity and plasticity of metabolism in breast cancer. Because differences in subtypes exhibit a bias toward metabolic pathways, targeting mitochondrial inhibitors shows great potential as stand-alone or adjuvant cancer therapies. Multiple therapeutic candidates are currently in various stages of preclinical studies and clinical openings. However, specific inhibitors have been shown to face multiple challenges (e.g., single metabolic therapies, mitochondrial structure and enzymes, etc.), and combining with standard therapies or targeting multiple metabolic pathways may be necessary. In this paper, we review the critical role of mitochondrial metabolic functions, including oxidative phosphorylation (OXPHOS), the tricarboxylic acid cycle, and fatty acid and amino acid metabolism, in metabolic reprogramming of breast cancer cells. In addition, we outline the impact of mitochondrial dysfunction on metabolic pathways in different subtypes of breast cancer and mitochondrial inhibitors targeting different metabolic pathways, aiming to provide additional ideas for the development of mitochondrial inhibitors and to improve the efficacy of existing therapies for breast cancer.

Schlagwörter

Stichwörter der Autor:innen

breast cancercancer subtypemetabolic reprogrammingmitochondrial inhibitorstumor progression

Autor:innen und Institutionen

  • Clinical Medical College, Southwest Medical University, Luzhou, China.
  • Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • Paediatrics Department, Southwest Medical University, Luzhou, China.
  • The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Biology Department, Southern Methodist University, Dallas, TX, United States.
  • Department of Specialty Medicine, Ohio University, Athens, OH, United States.

Zitieren

APA

Yan, Y., Li, S., Su, L., Tang, X., Chen, X., Gu, X., Yang, G., Chi, H., & Huang, S. (2024). Mitochondrial inhibitors: a new horizon in breast cancer therapy. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1421905

Vancouver

Yan Y, Li S, Su L, Tang X, Chen X, Gu X, et al. Mitochondrial inhibitors: a new horizon in breast cancer therapy. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1421905

BibTeX
@article{Yan2024,
  author = {Yan, Yalan and Li, Sijie and Su, Lanqian and Tang, Xinrui and Chen, Xiaoyan and Gu, Xiang and Yang, Guanhu and Chi, Hao and Huang, Shangke},
  title = {Mitochondrial inhibitors: a new horizon in breast cancer therapy},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1421905}
}
Kostenlos starten →